Keros Therapeutics (KROS) reported a second-quarter 2026 net loss of $28.7 million, compared with a net loss of $30.7 million in the same quarter of 2025. The clinical-stage biopharmaceutical company reported no total revenue for the quarter, compared with $18.2 million a year earlier.
Keros said it initiated a Phase 2 clinical trial evaluating rinvatercept in patients with Duchenne muscular dystrophy and continues to expect initial data in the first half of 2027. Cash and cash equivalents were $257.6 million as of June 30, 2026, with the company expecting funding into the first half of 2028.
- Net loss was $28.7 million, versus $30.7 million in Q2 2025.
- Basic and diluted net loss per share was $1.45.
- Research and development expenses were $22.3 million, down from $43.5 million a year earlier.
- General and administrative expenses were $8.6 million, down from $14.5 million a year earlier.
- Cash and cash equivalents were $257.6 million at quarter-end.
$KROS Insider Trading Activity
$KROS insiders have traded $KROS stock on the open market 12 times in the past 6 months. Of those trades, 4 have been purchases and 8 have been sales.
Here’s a breakdown of recent trading of $KROS stock by insiders over the last 6 months:
- JASBIR SEEHRA (CHIEF EXECUTIVE OFFICER) sold 7,015 shares for an estimated $113,432
- ESTHER CHO (SVP, General Counsel) sold 4,745 shares for an estimated $77,580
- KEITH REGNANTE (CHIEF FINANCIAL OFFICER) sold 4,739 shares for an estimated $77,482
- LORENA RAQUEL LERNER (Chief Science Officer) sold 3,873 shares for an estimated $63,323
- JEAN JACQUES BIENAIME has made 4 purchases buying 5,000 shares for an estimated $54,920 and 0 sales.
- NIMA FARZAN sold 2,625 shares for an estimated $28,166
- JULIUS KNOWLES sold 2,625 shares for an estimated $28,166
- ALPNA SETH sold 2,625 shares for an estimated $28,140
- CHARLES W. NEWTON sold 550 shares for an estimated $5,521
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$KROS Hedge Fund Activity
We have seen 56 institutional investors add shares of $KROS stock to their portfolio, and 87 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- NANTAHALA CAPITAL MANAGEMENT, LLC added 1,000,000 shares (+277.5%) to their portfolio in Q1 2026, for an estimated $11,040,000
- ARROWSTREET CAPITAL, LIMITED PARTNERSHIP removed 744,267 shares (-55.8%) from their portfolio in Q1 2026, for an estimated $8,216,707
- STATE STREET CORP removed 514,263 shares (-47.8%) from their portfolio in Q1 2026, for an estimated $5,677,463
- GOLDMAN SACHS GROUP INC removed 366,038 shares (-62.0%) from their portfolio in Q1 2026, for an estimated $4,041,059
- DIMENSIONAL FUND ADVISORS LP added 263,347 shares (+453.9%) to their portfolio in Q1 2026, for an estimated $2,907,350
- WEISS ASSET MANAGEMENT LP removed 254,063 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $2,804,855
- AQR CAPITAL MANAGEMENT LLC added 226,020 shares (+125.2%) to their portfolio in Q1 2026, for an estimated $2,495,260
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
